Combine searches by placing the search numbers in the top search box and pressing the search button. An example search might look like (#1 or #2) and (#3 or #4)
Loading history...
Latest & greatest articles for multiple sclerosis
The Trip Database is a leading resource to help health professionals find trustworthy answers to their clinical questions. Users can access the latest research evidence and guidance to answer their clinical questions. We have a large collection of systematic reviews, clinical guidelines, regulatory guidance, clinical trials and many other forms of evidence. If you wanted the latest trusted evidence on multiple sclerosis or other clinical topics then use Trip today.
This page lists the very latest high quality evidence on multiple sclerosis and also the most popular articles. Popularity measured by the number of times the articles have been clicked on by fellow users in the last twelve months.
What is Trip?
Trip is a clinical search engine designed to allow users to quickly and easily find and use high-quality research evidence to support their practice and/or care.
Trip has been online since 1997 and in that time has developed into the internet’s premier source of evidence-based content. Our motto is ‘Find evidence fast’ and this is something we aim to deliver for every single search.
As well as research evidence we also allow clinicians to search across other content types including images, videos, patient information leaflets, educational courses and news.
For further information on Trip click on any of the questions/sections on the left-hand side of this page. But if you still have questions please contact us via jon.brassey@tripdatabase.com
Ozanimod (supplied as ozanimod hydrochloride) - Zeposia - relapsing remitting multiplesclerosis Search Page - Drug and Health Product Register Language selection Search and menus Search Search website Search Topics menu You are here: Summary Basis of Decision - - Health Canada Expand all Summary Basis of Decision (SBD) for Contact: Summary Basis of Decision (SBD) documents provide information related to the original authorization of a product. The for is located below. Recent Activity for SBDs
Siponimod (multiplesclerosis) - Addendum to Commission A20-10 1 Translation of addendum A20-51 Siponimod (multiple Sklerose) – Addendum zum Auftrag A20-10 (Version 1.0; Status: 16 July 2020). Please note: This translation is provided as a service by IQWiG to English- language readers. However, solely the German original text is absolutely authoritative and legally binding. Addendum 16 July 2020 1.0 Commission: A20-51 Version: Status: IQWiG Reports – Commission No. A20-51 Siponimod (multiple (...) sclerosis) – Addendum to Commission A20-10 1 Addendum A20-51 Version 1.0 Siponimod – Addendum to Commission A20-10 16 July 2020 Institute for Quality and Efficiency in Health Care (IQWiG) - i - Publishing details Publisher Institute for Quality and Efficiency in Health Care Topic Siponimod (multiplesclerosis) – Addendum to Commission A20-10 Commissioning agency Federal Joint Committee Commission awarded on 23 June 2020 Internal Commission No. A20-51 Address of publisher Institut für Qualität und
Siponimod (multiplesclerosis) - Benefit assessment according to §35a Social Code Book V 1 Translation of Sections 2.1 to 2.5 of the dossier assessment Siponimod (multiple Sklerose) – Nutzenbewertung gemäß § 35a SGB V (Version 1.0; Status: 13 May 2020). Please note: This translation is provided as a service by IQWiG to English-language readers. However, solely the German original text is absolutely authoritative and legally binding. Extract IQWiG Reports – Commission No. A20-10 Siponimod (...) (multiplesclerosis) – Benefit assessment according to §35a Social Code Book V 1 Extract of dossier assessment A20-10 Version 1.0 Siponimod (multiplesclerosis) 13 May 2020 Institute for Quality and Efficiency in Health Care (IQWiG) - i - Publishing details Publisher Institute for Quality and Efficiency in Health Care Topic Siponimod (multiplesclerosis) – Benefit assessment according to §35a Social Code Book V Commissioning agency Federal Joint Committee Commission awarded on 5 February 2020 Internal
Siponimod (Mayzent) - secondary progressive multiplesclerosis (SPMS) 1 Published 12 October 2020 1 SMC2265 siponimod 250 microgram and 2mg film-coated tablets (Mayzent®) Novartis Pharmaceuticals UK Ltd 04 September 2020 The Scottish Medicines Consortium (SMC) has completed its assessment of the above product and advises NHS Boards and Area Drug and Therapeutic Committees (ADTCs) on its use in NHSScotland. The advice is summarised as follows: ADVICE: following a full submission siponimod (...) (Mayzent®) is accepted for use within NHSScotland. Indication under review: treatment of adult patients with secondary progressive multiplesclerosis (SPMS) with active disease evidenced by relapses or imaging features of inflammatory activity. In a randomised, double-blind, placebo-controlled phase III study, siponimod was associated with a reduction in disability progression confirmed after 3 months in patients with SPMS. This advice applies only in the context of an approved NHSScotland Patient
Ofatumumab versus Teriflunomide in MultipleSclerosis. Ofatumumab, a subcutaneous anti-CD20 monoclonal antibody, selectively depletes B cells. Teriflunomide, an oral inhibitor of pyrimidine synthesis, reduces T-cell and B-cell activation. The relative effects of these two drugs in patients with multiplesclerosis are not known.In two double-blind, double-dummy, phase 3 trials, we randomly assigned patients with relapsing multiplesclerosis to receive subcutaneous ofatumumab (20 mg every 4 weeks (...) neurofilament light chain levels, but not the change in brain volume, were in the same direction as the primary end point. Injection-related reactions occurred in 20.2% in the ofatumumab group and in 15.0% in the teriflunomide group (placebo injections). Serious infections occurred in 2.5% and 1.8% of the patients in the respective groups.Among patients with multiplesclerosis, ofatumumab was associated with lower annualized relapse rates than teriflunomide. (Funded by Novartis; ASCLEPIOS I and II
The Effect of Transcranial Direct Current Stimulation on Chronic Neuropathic Pain in Patients with MultipleSclerosis: Randomized Controlled Trial The Effect of Transcranial Direct Current Stimulation on Chronic Neuropathic Pain in Patients with MultipleSclerosis: Randomized Controlled Trial - PubMed This site needs JavaScript to work properly. Please enable it to take advantage of the complete set of features! Clipboard, Search History, and several other advanced features are temporarily (...) on Chronic Neuropathic Pain in Patients with MultipleSclerosis: Randomized Controlled Trial , , , Affiliations Expand Affiliations 1 Rehabilitation Department, Royal Melbourne Hospital, Royal Park Campus, Melbourne, Australia. 2 Department of Medicine and Radiology, Integrated Critical Care, University of Melbourne, Melbourne, Australia. 3 Department of Rehabilitation, Nutrition and Sport, Discipline of Physiotherapy, School of Allied Health, La Trobe University, Melbourne, Australia. 4 Department
EAN guideline on palliative care of people with severe, progressive multiplesclerosis EAN guideline on palliative care of people with severe, progressive multiplesclerosis A. Solari a , A. Giordano a,b , J. Sastre-Garriga c ,S.K€ opke d,e , A. C. Rahn e , I. Kleiter f , K. Aleksovska g , M. A. Battaglia h , J. Bay i , M. Copetti j , J. Drulovic k , L. Kooij l , J. Mens l , E. R. Meza Murillo c , I. Milanov m , R. Milo n,o , T. Pekmezovic p , J. Vosburgh q , E. Silber r , S. Veronese s , F (...) . Patti t , R. Voltz u,v , D. Oliver w and on behalf of the guideline task force , * a Unit of Neuroepidemiology, Fondazione IRCCS Istituto Neurologico Carlo Besta, Milan; b Department of Psychology, University of Turin, Turin, Italy; c Department of Neurology/Neuroimmunology, MultipleSclerosis Centre of Catalonia (Cemcat), Hospital Universitari Vall d’Hebron, Universitat Aut onoma de Barcelona, Barcelona, Spain; d Institute of Clinical Nursing Science, University of Cologne, Cologne; e Institute
Amiloride, fluoxetine or riluzole to reduce brain volume loss in secondary progressive multiplesclerosis: the MS-SMART four-arm RCT Amiloride, fluoxetine or riluzole to reduce brain volume loss in secondary progressive multiplesclerosis: the MS-SMART four-arm RCT Journals Library An error occurred retrieving content to display, please try again. >> >> >> Page Not Found Page not found (404) Sorry - the page you requested could not be found. Please choose a page from the navigation or try (...) Stutters 1 , David MacManus 1 , Ferran Prados 1, 4, 5 , Ian Marshall 2 , Bhavana Solanky 1 , Rebecca S Samson 1 , Frederik Barkhof 1, 4, 6 , Sebastien Ourselin 7 , Marie Braisher 1 , Moira Ross 3 , Gina Cranswick 3 , Sue H Pavitt 8 , Sharmilee Gnanapavan 9 , Gavin Giovannoni 9 , Claudia AM Gandini Wheeler-Kingshott 1, 10 , Clive Hawkins 11 , Basil Sharrack 12 , Roger Bastow 13 , Christopher J Weir 3 , Nigel Stallard 14 , Siddharthan Chandran 2 , Jeremy Chataway 1, 15, * 1 Queen Square Multiple
Dietary interventions for multiplesclerosis-related outcomes. Multiplesclerosis (MS) is a common demyelinating disease of the central nervous system. Although the exact pathogenesis remains unknown, the leading theory is that it results from immune system dysregulation. Approved disease-modifying therapy appears to modulate the immune system to improve MS-related outcomes. There is substantial interest in the ability of dietary interventions to influence MS-related outcomes. This is an update (...) of the Cochrane Review 'Dietary interventions for multiplesclerosis' (Farinotti 2003; Farinotti 2007; Farinotti 2012).To assess the effects of dietary interventions (including dietary plans with recommendations for specific whole foods, macronutrients, and natural health products) compared to placebo or another intervention on health outcomes (including MS-related outcomes and serious adverse events) in people with MS.On 30 May 2019, we searched CENTRAL, MEDLINE, Embase, and Web of Science. We also searched
Siponimod (Mayzent) - multiplesclerosis Search Page - Drug and Health Product Register Language selection Search and menus Search Search website Search Topics menu You are here: Summary Basis of Decision - - Health Canada Expand all Summary Basis of Decision (SBD) for Contact: Summary Basis of Decision (SBD) documents provide information related to the original authorization of a product. The for is located below. Recent Activity for SBDs written for approved after September 1, 2012
Ozanimod (Zeposia) - To treat relapsing forms of multiplesclerosis Drug Approval Package: ZEPOSIA U.S. Department of Health and Human Services Search FDA Submit search Drug Approval Package: ZEPOSIA Company: Celgene Corporation Application Number: 209899 Approval Date: 03/20/2020 Persons with disabilities having problems accessing the PDF files below may call (301) 796-3634 for assistance. FDA Approval Letter and Labeling (PDF) (PDF) FDA Application Review Files (PDF) (PDF) (PDF) (PDF) (PDF
Fampridine (Fampyra) - For the improvement of walking in adult patients with multiplesclerosis 1 Published 13 April 2020 1 SMC2253 fampridine 10mg prolonged-release tablet (Fampyra®) Biogen Idec Ltd 06 March 2020 The Scottish Medicines Consortium (SMC) has completed its assessment of the above product and advises NHS Boards and Area Drug and Therapeutic Committees (ADTCs) on its use in NHSScotland. The advice is summarised as follows: ADVICE: following a second resubmission fampridine (Fampyra (...) ® ) is accepted for use within NHSScotland. Indication under review: For the improvement of walking in adult patients with multiplesclerosis with walking disability (EDSS [expanded disability status scale] 4-7). In double-blind phase III studies fampridine, compared with placebo, improved walking ability in adults with multiplesclerosis and walking impairment. This advice applies only in the context of an approved NHSScotland Patient Access Scheme (PAS) arrangement delivering the cost
Disease modifying drugs for treatment of primary progressive multiplesclerosis: A health technology assessment Disease modifying drugs for treatment of primary progressive multiplesclerosis: A health technology assessment - NIPH Search for: Søk Menu To top level Close Infectious diseases & Vaccines Mental & Physical health Environment & Lifestyle Health in Norway Quality & Knowledge Research & Access to data About NIPH Close Disease modifying drugs for treatment of primary progressive (...) multiplesclerosis: A health technology assessment Order Download: Key message We have systematically collected and reviewed the evidence for clinical efficacy for disease modifying treatments for PPMS. We included three randomised placebo-controlled trials that each compare the effect of one medication (either fingolimod, ocrelizumab or rituximab, respectively) with placebo. For each of the three drugs, we calculated the risk ratios for confirmed disease progression. We also report results in the form